生物活性

• 描述Cefpodoxime proxetil is an oral third generation cephalosporin with a broad spectrum of antibacterial activity. The drug has in vitro activity against many common Gram-positive and Gram-negative pathogens associated with common paediatric infections. Cefpodoxime 8 to 10 mg/kg/day (administered in 2 divided doses) for 5 to 10 days was at least as effective as standard 10-day regimens of penicillin V in the treatment of children with pharyngitis and/or tonsillitis. Significant differences in favour of cefpodoxime proxetil were demonstrated in terms of clinical (1 study) and bacteriological (2 studies) criteria. Cefpodoxime proxetil is well tolerated by paediatric patients, with adverse events (primarily gastrointestinal tract disturbances and skin rashes) that are consistent with those reported for other oral cephalosporins^[1]. A single oral dose of cefpodoxime was also as efficacious as ceftriaxone in uncomplicated anogenital gonococcal infections^[2]. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis^[3]. Cefpodoxime is well tolerated by children and is effective in the treatment of otitis media and pharyngitis. It has a similar adverse effect profile to that of other penicillins and cephalosporins, with gastrointestinal effects being most common^[4].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02829060	Nephrolithiasis ... more >> Urinary Tract Infection (UTI) Sepsis Collapse <<	Not Applicable	Recruiting	January 2019	United States, California ... more >> University of California San Diego Recruiting San Diego, California, United States, 92101 Contact: Roger L Sur, MD    619-543-2628    rlsur@ucsd.edu    Contact: Joel E Abbott, DO    619-543-2628    jabbott@westernu.edu    Sub-Investigator: Seth K Bechis, MD Collapse <<
  NCT01502878	Nut Allergy	Not Applicable	Completed	-	Finland ... more >> Helsinki University Central Hospital, Skin and Allergy Hospital Helsinki, Finland, 00029 Helsinki University Central Hospital, Skin and Allergy Hospital Helsinki, Finland, 160 Collapse <<
  NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... more >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Collapse <<

• 更多
• 参考文献

• [1] Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatr Drugs. 2001;3(2):137‐158

  [2] Frampton JE, Brogden RN, Langtry HD, Buckley MM. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992;44(5):889‐917

  [3] Iqbal S, Hassan S, Hassan A, et al. In vitro Spectroscopic studies on drug interaction of cefpodoxime proxetil and H2 receptor blockers. Pak J Pharm Sci. 2019;32(2 (Supplementary)):881‐887

  [4] Chocas EC, Paap CM, Godley PJ. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin. Ann Pharmacother. 1993;27(11):1369‐1377